NCT04039958 - A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

May 13, 2017

Study Completion Date

May 28, 2017

Conditions

Healthy

Interventions

DRUG

Soviredia

Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

DRUG

Harvoni (first dose)

Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

DRUG

Harvoni (Second dose)

Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Trial Locations (1)

Genuine Research Center GRC, Cairo